
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is a biotechnology company that uses its proprietary DDX platform to develop gene therapies for diseases with high unmet clinical needs, such as Non-Muscle Invasive Bladder Cancer (NMIBC). With promising results from its pivotal LEGEND Phase 2 trial and a strong cash reserve of $266.3M, enGene is well-positioned to move towards BLA submission in 4Q26 and potential FDA approval. However, key questions regarding durability, competitive efficacy and durability data, and NCCN guideline inclusion remain, along with risks such as clinical, regulatory, and financial challenges, which could impact the company's share price and future success.
Bears say
enGene Therapeutics is developing a gene therapy product, detalimogene, for Non-Muscle Invasive Bladder Cancer (NMIBC) patients. While initial data showed potential for this product, recent updates have shown a decline in response rates and durability compared to other competitors in the market. Additionally, the company's financials show an increase in operating expenses and a decrease in cash, causing concerns about their ability to effectively bring this product to market. Questions remain about the efficacy and potential of detalimogene, as well as the company's regulatory strategy and financial stability, leading to a negative outlook on their stock.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares